48 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
14 May 24
Candel Therapeutics Reports First Quarter 2024 Financial Results
8:15am
2024
Financial Results for First Quarter Ended March 31, 2024
Research and Development Expenses: Research and development expenses were $4.1 million … for CAN-2409 programs. Research and development expenses included non-cash stock compensation expense of $0.6 million for the first quarter of 2024
8-K
EX-99.1
CADL
Candel Therapeutics Inc
28 Mar 24
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
7:45am
December 31, 2023
Research and Development Service Revenue, related party: Research and development service revenue, related party, for each of the quarter … and Development Expenses: Research and development expenses were $7.3 million for the fourth quarter of 2023 compared to $5.0 million for the fourth
8-K
EX-99.1
xzidnt0u5do 8ue
9 Nov 23
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
8:16am
8-K
EX-99.1
o4z16
10 Aug 23
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
8:15am
8-K
EX-99.1
4iuvs6d3u7j m80
8 Jun 23
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
8:15am
8-K
EX-99.1
j1zzrio3o
11 May 23
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
8:31am
8-K
EX-99.1
qtpg5
30 Mar 23
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
8:30am
8-K
EX-99.1
aqo r744ct
6 Dec 22
Other Events
5:30pm
8-K
c244hn4cqp9v 3i
6 Dec 22
Other Events
5:30pm
8-K
EX-99.1
7tlsu 9sdvi
6 Dec 22
Regulation FD Disclosure
8:01am
8-K
h2p654k
6 Dec 22
Regulation FD Disclosure
8:01am
8-K
EX-99.1
e5m43hkas3qg0pw
29 Nov 22
Regulation FD Disclosure
8:31am
8-K
sr9 d7xjw5
29 Nov 22
Regulation FD Disclosure
8:31am